-49%

est. 2Y upside i

Series B

Rank

#1882

Sector

FoodTech

Est. Liquidity

~4Y

Data Quality

Data: Medium

Wildtype presents a moderate upside opportunity for a job seeker, driven by its pioneering FDA approval for cultivated salmon and strong investor backing in a nascent, high-potential market.

Last updated: March 10, 2026

Bull (30%)+200%

Wildtype successfully scales production, achieves significant cost reductions, and overcomes state-level bans through legal victories and expanded federal acceptance. This leads to widespread consumer adoption and new product lines, pushing revenue to over $300M by 2028 and justifying a $1.8B+ valuation, establishing Wildtype as a leader in sustainable seafood.

Base (35%)+50%

Wildtype achieves steady growth in select markets, leveraging its FDA approval and early-mover advantage, but faces persistent regulatory hurdles in some states and moderate competition. Revenue grows to ~$100M-$120M by 2028, leading to a $900M valuation, reflecting solid but not explosive market penetration.

Bear (35%)-70%

State-level bans on cultivated meat sales expand or persist, significantly limiting market access. High capital intensity and slower-than-expected consumer adoption lead to continued high burn and a down round, with valuation dropping to $180M, severely impacting common stock value.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Investors hold approximately $127M in liquidation preferences, representing about 21.16% of the estimated current valuation of $600M.

Dilution Risk

high

The very high capital intensity suggests Wildtype will require additional significant funding rounds, which will likely lead to further dilution for existing equity holders.

Secondary Liquidity

none

As a privately held Series B company, there is currently no active secondary market for Wildtype shares, limiting immediate liquidity options for employees.

Questions to Ask at the Interview

Strategic questions based on WildType's data — designed to show you've done your homework.

  • 1

    “Given the ongoing state-level bans and lawsuits, what is Wildtype's long-term strategy for navigating and ultimately overcoming these regulatory challenges to achieve nationwide market access?”

  • 2

    “With a revenue of ~$65M and very high capital intensity, how does Wildtype plan to achieve significant cost reductions and scale production to reach price parity with traditional seafood, and what are the key milestones for this over the next 2-3 years?”

  • 3

    “Considering the Series B funding and the current market landscape, what is the anticipated timeline and most likely path to a liquidity event (e.g., IPO or acquisition) for employees, and how is the company managing potential dilution for common stock holders in future funding rounds?”

Community

Valuation Sentiment

Our model estimates -49% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.